Ascendis Pharma A/S (ASND1N)

Profile

https://ascendispharma.com

Ascendis Pharma A/S is a Denmark-based biopharmaceutical company that develops and commercializes therapies for serious diseases using its proprietary TransCon technology platform. The company’s primary focus is on endocrinology rare diseases, where it offers SKYTROFA for pediatric growth hormone deficiency and YORVIPATH for adults with chronic hypoparathyroidism, alongside additional clinical candidates targeting conditions such as adult growth hormone deficiency and achondroplasia. Ascendis Pharma also advances oncology programs, including immunotherapy and targeted therapy candidates built on the same TransCon approach to achieve predictable, sustained delivery of parent drugs. Operating through research facilities in Germany and commercial and clinical operations across Europe, North America, and other regions, Ascendis Pharma positions itself as a global player in specialty healthcare markets. Incorporated in 2006 and headquartered in Hellerup, Denmark, the company serves physicians, hospitals, and specialized treatment centers that manage rare endocrine disorders and oncology indications.